



US008742101B2

(12) **United States Patent**
Storer et al.

(10) **Patent No.:** **US 8,742,101 B2**
(45) **Date of Patent:** **Jun. 3, 2014**

- (54) **PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C**
- (75) Inventors: **Richard Storer**, Folkestone (GB); **Gilles Gosselin**, Montpellier (FR); **David Dukhan**, Montpellier (FR); **Frederic Leroy**, Jonquieres (FR)
- (73) Assignees: **Idenix Pharmaceuticals, Inc.**, Cambridge, MA (US); **Centre National de la Recherche Scientifique**, Paris (FR); **L'Universite Montpellier II**, Montpellier (FR)

| | | | |
|-----------|----|---------|---------------------|
| 5,633,358 | A | 5/1997 | Gruetzke et al. |
| 5,676,942 | A | 10/1997 | Testa et al. |
| 5,725,859 | A | 3/1998 | Omer |
| 5,738,845 | A | 4/1998 | Imakawa |
| 5,830,455 | A | 11/1998 | Valtuna et al. |
| 5,837,257 | A | 11/1998 | Tsai et al. |
| 5,846,964 | A | 12/1998 | Ozeki |
| 5,849,696 | A | 12/1998 | Chretien et al. |
| 5,869,253 | A | 2/1999 | Draper |
| 5,874,565 | A | 2/1999 | Rice et al. |
| 5,891,874 | A | 4/1999 | Colacino et al. |
| 5,990,276 | A | 11/1999 | Zhang et al. |
| 6,004,933 | A | 12/1999 | Spruce et al. |
| 6,034,134 | A | 3/2000 | Gold et al. |
| 6,043,077 | A | 3/2000 | Barber et al. |
| 6,056,961 | A | 5/2000 | Lavie et al. |
| 6,100,024 | A | 8/2000 | Hudson et al. |
| 6,326,151 | B1 | 12/2001 | Katze et al. |
| 6,340,690 | B1 | 1/2002 | Bachand et al. |
| 6,348,587 | B1 | 2/2002 | Schinazi et al. |
| 6,379,886 | B1 | 4/2002 | Takahama et al. |
| 6,403,566 | B1 | 6/2002 | Wang |
| 6,410,531 | B1 | 6/2002 | Llina-Brunet et al. |
| 6,416,944 | B1 | 7/2002 | Chien et al. |
| 6,416,946 | B1 | 7/2002 | Chien et al. |
| 6,420,380 | B2 | 7/2002 | Llina-Brunet et al. |
| 6,436,666 | B1 | 8/2002 | Chien et al. |
| 6,495,677 | B1 | 12/2002 | Ramasamy et al. |
| 6,534,523 | B1 | 3/2003 | Llina-Brunet et al. |

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 513 days.

(21) Appl. No.: **12/270,795**

(22) Filed: **Nov. 13, 2008**

(65) **Prior Publication Data**

US 2009/0169507 A1 Jul. 2, 2009

Related U.S. Application Data

(63) Continuation of application No. 10/900,008, filed on Jul. 26, 2004, now abandoned.

(60) Provisional application No. 60/490,216, filed on Jul. 25, 2003.

(51) **Int. Cl.**

| | |
|--------------------|-----------|
| C07H 19/12 | (2006.01) |
| C07H 19/056 | (2006.01) |
| C07H 19/04 | (2006.01) |
| C07D 487/04 | (2006.01) |
| A61K 31/53 | (2006.01) |
| A61K 31/341 | (2006.01) |
| A61P 31/14 | (2006.01) |

(52) **U.S. Cl.**

USPC **544/180**; 536/27.13; 514/241; 514/245; 514/43; 514/45; 514/48

(58) **Field of Classification Search**

USPC 544/180; 536/27.13; 514/241, 245, 43, 514/45, 48, 44; 1/180

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | | |
|-----------|---|---------|------------------|
| 3,798,209 | A | 3/1974 | Witkowski et al. |
| RE29,835 | E | 11/1978 | Witkowski et al. |
| 4,211,771 | A | 7/1980 | Witkowski et al. |
| 4,522,811 | A | 6/1985 | Eppstein et al. |
| 5,026,687 | A | 6/1991 | Yarchoan et al. |
| 5,055,394 | A | 10/1991 | Kopecko et al. |
| 5,149,794 | A | 9/1992 | Yatvin et al. |
| 5,194,654 | A | 3/1993 | Hostetler et al. |
| 5,223,263 | A | 6/1993 | Hostetler et al. |
| 5,372,808 | A | 12/1994 | Blatt et al. |
| 5,496,546 | A | 3/1996 | Wang et al. |
| 5,538,865 | A | 7/1996 | Reyes et al. |
| 5,610,054 | A | 3/1997 | Drapper |

FOREIGN PATENT DOCUMENTS

| | | |
|----|-------------|---------|
| DE | 19914474 | 10/1999 |
| EP | 0350287 | 1/1990 |
| EP | 0650371 | 5/1995 |
| EP | 1043399 | 10/2000 |
| JP | 03-148278 | 6/1991 |
| JP | 05-111389 | 5/1993 |
| JP | 08268890 | 10/1996 |
| JP | 10101591 | 4/1998 |
| WO | WO 88/02785 | 4/1988 |
| WO | WO 89/02733 | 4/1989 |

(Continued)

OTHER PUBLICATIONS

Wolft Manfred E. "Burger's Medicinal Chemistry, 5ed, Part 1", John Wiley & Sons, 1995, pp. 975-977.*

(Continued)

Primary Examiner — Venkataraman Balasubramanian

(74) Attorney, Agent, or Firm — Jones Day

(57) **ABSTRACT**

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a salt or prodrug thereof, may be administered alone or in combination with one or more optionally substituted pentofuranonucleosides or other anti-viral agents.

38 Claims, 3 Drawing Sheets